Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10376 in Advanced NSCLC
NCT05435274Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HS-10376 in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 24 months. Started Sep 2021; status: recruiting.
02
Drugs
HS-10376
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05435274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05435274.